瑞齐替尼对比吉非替尼一线治疗EGFR突变晚期非小细胞肺癌的3期研究
REZOR研究为多中心双盲3期试验,纳入369例EGFR突变晚期NSCLC患者,随机接受瑞齐替尼180mg或吉非替尼250mg一线治疗。
要点
- 3级及以上治疗相关不良事件两组相似(23% vs 23%)。
- 瑞齐替尼组发生1例治疗相关死亡(肺炎和间质性肺病)。
核心结论
- 瑞齐替尼作为EGFR突变晚期NSCLC一线治疗,相比吉非替尼显著改善无进展生存期,且未发现新安全性信号。
研究设计与样本
- 多中心、双盲、随机、3期研究(REZOR),中国50家医院,369例EGFR外显子19缺失或外显子21 Leu858Arg突变的局部晚期或转移性NSCLC患者随机1:1接受瑞齐替尼180mg/日或吉非替尼250mg/日。
主要发现
- 预设亚组疗效分析结果一致。
- 3级及以上治疗中出现的不良事件:瑞齐替尼组45%(82/184),吉非替尼组43%(80/185)。
- 治疗相关不良事件:两组均为23%(瑞齐替尼组43/184,吉非替尼组43/185)。
- 瑞齐替尼组1例治疗相关死亡(肺炎和间质性肺病)。
关键数值与推荐
- 瑞齐替尼180mg每日一次,吉非替尼250mg每日一次,21天为一周期。
- 主要终点为意向治疗人群的盲态独立中心评估的无进展生存期。
临床怎么用
- 瑞齐替尼可作为EGFR突变局部晚期或转移性NSCLC患者的一线治疗选择。
局限性
- 随访仍在进行中。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: This study aimed to compare the efficacy and safety of rezivertinib (BPI-7711) and gefitinib as first-line therapies in patients with EGFR-mutated locally advanced or metastatic non-small-cell lung cancer (NSCLC). METHODS: This multicentre, double-blind, randomised, phase 3 study (REZOR) included eligible patients from 50 hospitals across China. Those who had been histologically or cytologically confirmed as having NSCLC with EGFR exon 19 deletion or exon 21 Leu858Arg mutation by central laboratory were randomly assigned (1:1) to receive once daily either rezivertinib 180 mg or gefitinib 250 mg, until unacceptable toxicity occurred, disease progression, or other treatment discontinuation criteria were met. Each cycle lasted for 21 days. The primary endpoint was progression-free survival evaluated by masked independent central review (MICR) in the intention-to-treat set. This trial is registered with ClinicalTrials.gov, NCT03866499 and follow-up is ongoing. FINDINGS: Between July 15, 2019, and Feb 14, 2022, 695 patients were screened. Among them, 369 eligible patients were randomly assigned to receive either rezivertinib 180 mg/day plus placebo (n=184) or gefitinib 250 mg/day plus placebo (n=185) in a 1:1 ratio; all of eligible participants were included in the intention-to-treat set. Median MICR-assessed progression-free survival was 19·3 months (95% CI 13·8-22·1) in the rezivertinib group and 9·6 months (8·4-11·3) in the gefitinib group (hazard ratio [HR] 0·48, 95% CI 0·36-0·63; p<0·0001) and the prespecified subgroup efficacy analysis showed consistent results. Median duration of exposure was 16·0 months (95% CI 0·0-29·7) in the rezivertinib group and 11·0 months (0·0-28·9) in the gefitinib group. Grade 3 or higher treatment-emergent adverse events (82 [45%] of 184 in the rezivertinib group; 80 [43%] of 185 in the gefitinib group) and treatment-related adverse events (TRAEs; 43 [23%] of 184 in the rezivertinib group; 43 [23%] of 185 in the gefitinib group) were similar in both groups. One patient died from a TRAE in the rezivertinib group, due to pneumonia and interstitial lung disease. INTERPRETATION: Our findings suggested that rezivertinib is a potential choice for patients with EGFR-mutated locally advanced or metastatic NSCLC as first-line therapy, owing to the superior overall efficacy and subgroup progression-free survival compared with gefitinib in targeted patients. No new safety signals were identified. FUNDING: Beta Pharma (Shanghai) and the China National Science and Technology Major Project for Key New Drug Development.
引用
- Shi Y, Guo Y, Li X, et al. Rezivertinib versus gefitinib as first-line therapy for patients with EGFR-mutated locally advanced or metastatic non-small-cell lung cancer (REZOR): a multicentre, double-blind, randomised, phase 3 study. Lancet Respir Med. 2025. PMID: 39914443. doi:10.1016/S2213-2600(24)00417-X
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。